drugset / Trial / NCT02089633
Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC
Phase 2
Completed
17 enrolled
Bio-Cancer Treatment International Limited
The University of Hong Kong · collab
NaSingle-groupOpen-labelTreatment
Summary
The propose of the study is to evaluate the maximum tolerated dose (MTD) of Oxaliplatin in combination with pegylated recombinant human arginase 1 (PEG-BCT-100) and Capecitabine and efficacy of this combination regimen (PACOX)in patients with advanced liver cancer.
Timeline
- Start
- 2014-04
- Primary completion
- 2016-09
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | Pegylated recombinant human arginase 1 | Protein / enzyme biologic | 2.7 mg/kg | Intravenous |